Loading clinical trials...

12-Week Efficacy Clinical Study of Serum | Clinical Trials | Clareo Health

COMPLETEDNA

12-Week Efficacy Clinical Study of Serum

NCT06968416•ChinaNorm

Summary

65 female adult subjects will be enrolled in the study, recruited according to inclusion and non-inclusion criteria listed above. At least 40 subjects should complete the clinical evaluation and 60 subjects should complete consumer questionnaire in this 15-week study (wash-out phase for 3 weeks and treatment phase for 12 weeks). Subjects will need to refrain from using any product other than the provided test products on whole face including eye area during the 3-week wash-out phase and 12-week study treatment phase.

Eligibility

Age

25 - 55 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•1. Chinese women aged from 25-55 years old.
•2. All skin types, including 50% sensitive skin.
•3. Regular users of serum with anti-aging need.
•4. Self-claim concerns of skin quality problem (radiance, smoothness, pore) and aging problems (fine lines, wrinkles, elasticity).
•5. Presenting with corresponding severity for the attribute evaluated by Dermatologist： Crows' feet wrinkle (Loreal atlas, 2≤grade≤5) Underneath Eye Wrinkle (Loreal atlas, 2≤grade≤5) Inter Ocular Wrinkles (Loreal atlas, 1\<grade≤4) Glabellar wrinkles (Loreal atlas, 1\<grade≤4) Nasolabial fold (Loreal atlas, 2≤grade≤4) Forehead wrinkle (Loreal atlas, 2≤grade≤5) Fine lines on the forehead (Loreal atlas, 1\<grade≤4) Cheek folds (Loreal atlas, 2≤grade≤5) Wrinkles of the corner of the lips (Loreal atlas, 1\<grade≤4)
•6. Clinical grading of skin pores, skin radiance and skin smoothness: 4≤grade≤6 evaluated by dermatologist.
•7. No disagreement of dermatologist because of other reasons that exclude the participation of the subject.
•8. In general good health at the time of the study.
•9. Willing and able to participate as evidenced by signing of informed consent and photo release form.
•10. Must be willing to comply with all study protocol requirements (pay attention to: only use the provided product during the study, not take topical or oral treatment like retinol, hormone, anti-oxidant health-care products which may impact the efficacy of study).

Exclusion Criteria

•1. Pregnant or breast-feeding woman or woman planning pregnancy during the study.
•2. Subject deprived of rights by a court or administrative order.
•3. Major subject to a guardianship order.
•4. Subject residing in a health or social care establishment.
•5. Patient in an emergency setting.
•6. Subject with a skin disease in the test areas (particularly e.g., acne, rosacea, eczema).
•7. Subject presenting a stable or progressive serious disease (per investigator's assessment).
•8. Immuno-compromised subject.
•9. Subject with history of allergy to cosmetic or personal care products or ingredients.
•10. Subject presenting excessive exposure to sunlight or UV radiation (investigator's assessment).
+5 more criteria

Locations (1)

Shanghai China-norm Quality Technical Service Co., Ltd.

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

August 2, 2023

Primary Completion Date

November 17, 2023

Completion Date

November 17, 2023

Last Updated

May 13, 2025

Enrollment

ACTUAL participants

Conditions

Anti-agingFemale

Interventions

Standard cleanser，standard moisturizer，standard sunscreen，Investigational serum

OTHER

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

NCT06126276

Malignant Female Reproductive System NeoplasmMalignant Solid Neoplasm+2 more

View study

RECRUITINGNA

MATCHING - feMAle geniTal sCHistosomiasis IN miGrants Female Genital Schistosomiasis in Migrants Presenting to an Outpatient Clinic in Italy: Prevalence and Clinical Impact

NCT07484256

Female Genital Schistosomiasis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 13, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

12-Week Efficacy Clinical Study of Serum

Inclusion Criteria

Exclusion Criteria

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

MATCHING - feMAle geniTal sCHistosomiasis IN miGrants Female Genital Schistosomiasis in Migrants Presenting to an Outpatient Clinic in Italy: Prevalence and Clinical Impact

Immune Cell Populations in the Endometrium

Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study

A Novel Approach in the Evaluation of Breast Masses With Doppler US

Efficacy and Safety of Gushen Antai Pill on Ongoing Pregnancy Rate in Women With Normal Ovarian Reserve Undergoing IVF-ET